Trial Profile
Long-term Documentation of the Utilization of Otezla in Patients With Plaque Psoriasis Under Routine Conditions (LAPIS-Pso)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Apr 2020
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms LAPIS-Pso
- Sponsors Celgene Corporation
- 08 Aug 2019 Status changed from active, no longer recruiting to completed.
- 12 Jun 2018 Planned End Date changed from 30 Dec 2017 to 15 Jul 2018.
- 12 Jun 2018 Planned primary completion date changed from 30 Jul 2017 to 14 Jun 2018.